The cancer diagnostics technology developer, formed five years ago when Qiagen acquired part of Enzymatics, has filed to float on the Nasdaq Global Market.

US-based genomic testing technology developer ArcherDX has filed to raise up to $100m in an initial public offering that would allow medical researcher Qiagen to exit.

ArcherDX has developed a system targeted at cancer that applies advanced genetic sequencing technology and bioinformatics software to the identification and discovery of genetic mutations.

The company was launched in 2015 after Qiagen acquired biological research technology provider Enzymatics’ Enzyme Solutions Unit. It sued Qiagen in mid-2018 alleging patent infringement and the trial…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.